Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic.
Sci Rep
; 10(1): 9294, 2020 06 09.
Article
in English
| MEDLINE | ID: covidwho-592060
ABSTRACT
As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Pneumonia, Viral
/
RNA-Dependent RNA Polymerase
/
Viral Nonstructural Proteins
/
Coronavirus Infections
/
Pandemics
/
Sofosbuvir
/
Betacoronavirus
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Sci Rep
Year:
2020
Document Type:
Article
Affiliation country:
S41598-020-66440-9
Similar
MEDLINE
...
LILACS
LIS